

Webinar on

Review Of Chemistry, Manufacturing And Controls (CMC) Of An Investigational New Drug Application (IND)

Learning Objectives

Outline of the relevance of information from the CMC perspective

Understanding differences between small molecules and Biologics

The glimpse of CFR 312.22 with the highlight of the FDA's primary objectives in reviewing an IND

Overview of Pre-IND activities

CMC package: IND content and Format with emphasis on the Drug Substance and Drug Product



This
webinar will
cover the
key aspects
of CMC
package. .

PRESENTED BY:

Gowri Sukumar is an Associate Director, CMC and Regulatory Affairs for ESSA Pharmaceuticals. Unique to her experience is leading all the technical disciplines of CMC development as well as Regulatory Affairs. She has broad responsibilities that include process development, Drug Substance, and Drug Product manufacturing from the CMC side.

On-Demand Webinar

Duration : 90 Minutes

Price: \$200

Webinar Description

This webinar is designed to help pharma companies through the various key aspects of the Chemistry Manufacturing and Controls (CMC) information expected by FDA in an IND (Investigational New Drug) Application. The presentation will cover the key aspects of CMC package. And will explore the individual requirements across both the Drug Substance as well as the Drug Product sections of the CMC package.



Who Should Attend ?

Regulatory affairs professionals

Senior management executives (CEO, COO, CFO, etc)


Drug discovery and development professionals (R&D and CMC)

Intellectual property experts

Project Managers and Clinical trial specialists

Regulatory Compliance Associates and Managers

People investing in FDA-regulated product development projects



To register please visit:

www.grceducators.com
support@grceducators.com
740 870 0321